Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts

Rheumatology (United Kingdom)

Volumn 51, Issue 12, 2012, Pages 2146-2154

  Shi Wen, Xu ^a   Thompson, Katherine ^b,c   Khan, Korsa ^a   Liu, Shangxi ^b   Murphy Marshman, Hannah ^b   Baron, Murray ^d   Denton, Christopher P ^a   Leask, Andrew ^b   Abraham, David J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b WESTERN UNIVERSITY   (Canada)

^c Fanshawe College   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

SMA; Adhesion; CCN2; Collagen; FAK; Integrin; ROS

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA1 INTEGRIN; COLLAGEN GEL; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; FOCAL ADHESION KINASE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; FIBROBLAST; FIBROSIS; GENE EXPRESSION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCLERODERMA; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; MALE; MICE; MYOFIBROBLASTS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION;

EID: 84870319857     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes234     Document Type: Article

References (43)

1. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
2. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117: 557-67.
3. Rajkumar VS, Howell K, Csiszar K et al. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 2005;7: R1113-23.
4. Chen Y, Shi-Wen X, van Beek J et al. Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 2005;67:1699-711.
5. Hinz B, Gabbiani G. Mechanisms of force generation and transmission by myofibroblasts. Curr Opin Biotechnol 2003;14:538-46.
6. Shi-Wen X, Renzoni EA, Kennedy L et al. Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol 2007;26:625-32.
7. Liu S, Kapoor M, Denton CP, Abraham DJ, Leask A. Loss of beta1 integrin in mouse fibroblasts results in resistance to skin scleroderma in a mouse model. Arthritis Rheum 2009;60:2817-21.
8. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci 2003;116:1409-16.
9. Mimura Y, Ihn H, Jinnin M et al. Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. J Invest Dermatol 2005;124:886-92.
10. Liu S, Shi-Wen X, Kennedy L et al. FAK is required for TGFbeta-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix-remodeling phenotype. Mol Biol Cell 2007;18:2169-78.
11. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
12. Shi-Wen X, Denton CP, McWhirter A et al. Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. Arthritis Rheum 1997;40:1237-44.
13. Kennedy L, Liu S, Shi-Wen X et al. CCN2 is necessary for the function of mouse embryonic fibroblasts. Exp Cell Res 2007;313:952-64.
14. Thompson K, Hamilton DW, Leask A. ALK5 inhibition blocks TGFb-induced CCN2 expression in gingival fibroblasts. J Dent Res 2010;89:1450-4.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DDCT) method. Methods 2001;25:402-8.
16. Shi-Wen X, Chen Y, Denton CP et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004;15: 2707-19.
17. Leask A, Shi-Wen X, Khan K et al. Loss of protein kinase Cepsilon results in impaired cutaneous wound closure and myofibroblast function. J Cell Sci 2008;121:3459-67.
18. Cabrita MA, Jones LM, Quizi JL et al. Focal adhesion kinase inhibitors are potent anti-angiogenic agents. Mol Oncol 2011;5:517-26.
19. Kennedy L, Shi-Wen X, Carter DE, Abraham DJ, Leask A. Fibroblast adhesion results in the induction of a matrix remodeling gene expression program. Matrix Biol 2008; 27:274-81.
20. Eckes B, Mauch C, Hüppe G, Krieg T. Differential regulation of transcription and transcript stability of pro-alpha 1(I) collagen and fibronectin in activated fibroblasts derived from patients with systemic scleroderma. Biochem J 1996;315:549-54.
21. Dugina V, Fontao L, Chaponnier C, Vasiliev J, Gabbiani G. Focal adhesion features during myofibroblastic differentiation are controlled by intracellular and extracellular factors. J Cell Sci 2001;114:3285-96.
22. Slack-Davis JK, Martin KH, Tilghman RW et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 2007;282:14845-52.
23. Holmes A, Abraham DJ, Sa S et al. CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem 2001;276:10594-601.
24. Abraham DJ, Shiwen X, Black CM et al. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000; 275:15220-5.
25. Dun ZN, Zhang XL, An JY et al. Specific shRNA targeting of FAK influenced collagen metabolism in rat hepatic stellate cells. World J Gastroenterol 2010;16:4100-6.
26. Hinz B. Tissue stiffness, latent TGF-beta1 activation, and mechanical signal transduction: implications for the pathogenesis and treatment of fibrosis. Curr Rheumatol Rep 2009;11:120-6.
27. Liu S, Xu SW, Blumbach K et al. Expression of integrin beta1 by fibroblasts is required for tissue repair in vivo. J Cell Sci 2010;123:3674-82.
28. Chiarugi P, Pani G, Giannoni E et al. Reactive oxygen species as essential mediators of cell adhesion: the oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion. J Cell Biol 2003;161:933-44.
29. Liu S, Kapoor M, Leask A. Rac1 expression by fibroblasts is required for tissue repair in vivo. Am J Pathol 2009;174: 1847-56.
30. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18:816-27.
31. Leask A. Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal 2008; 20:1409-14.
32. Kessler D, Dethlefsen S, Haase I et al. Fibroblasts in mechanically stressed collagen lattices assume a, 'synthetic' phenotype. J Biol Chem 2001;276: 36575-85.
33. Guo F, Carter DE, Leask A. Mechanical tension increases CCN2/CTGF expression and proliferation in gingival fibroblasts via a TGFb-dependent mechanism. PLoS One 2011;6:e19756.
34. van Nimwegen MJ, van de Water B. Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol 2007;73:597-609.
35. Lagares D, Busnadiego O, Garci{dotless}́a-Fernández RA et al. Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. Arthritis Rheum 2012;64:1653-64.
36. Thannickal VJ, Lee DY, White ES et al. Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem 2003;278:12384-9.
37. Leask A. Getting out of a sticky situation: targeting the myofibroblast in scleroderma. Open Rheumatol 2012;6: 163-9.
38. Sugiura H, Ichikawa T, Liu X et al. N-acetyl-L-cysteine inhibits TGF-beta1-induced profibrotic responses in fibroblasts. Pulm Pharmacol Ther 2009;22:487-91.
39. Felton VM, Borok Z, Willis BC. N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition. Am J Physiol Lung Cell Mol Physiol 2009;297:L805-12.
40. Behr J, Demedts M, Buhl R et al. Lung function in idiopathic pulmonary fibrosis-extended analyses of the IFIGENIA trial. Respir Res 2009;10:101.
41. Rosato E, Rossi C, Molinaro I et al. Long-term N-acetylcysteine therapy in systemic sclerosis interstitial lung disease: a retrospective study. Int J Immunopathol Pharmacol 2011;24:727-33.
42. Homma S, Azuma A, Taniguchi H et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology 2012;17:467-77.
43. Aitio ML. N-acetylcysteine-passe-partout or much ado about nothing? Br J Clin Pharmacol 2006;61: 5-15.